Imidazopyridyl compounds as aldosterone synthase inhibitors

• Published in: Bioorganic & medicinal chemistry letters Vol. 27; no. 2; pp. 143 - 146
• Main Authors: Whitehead, Brent R., Lo, Michael M.-C., Ali, Amjad, Park, Min K., Hoyt, Scott B., Xiong, Yusheng, Cai, Jiaqiang, Carswell, Emma, Cooke, Andrew, MacLean, John, Ratcliffe, Paul, Robinson, John, Bennett, D. Jonathan, Clemas, Joseph A., Wisniewski, Tom, Struthers, Mary, Cully, Doris, MacNeil, Douglas J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15-01-2017
• Subjects: Aldosterone; Animals; Cricetulus; CYP11B2; Cytochrome P-450 CYP11B2 - antagonists & inhibitors; Heart failure; Humans; Hypertension; Imidazoles - chemical synthesis; Imidazoles - chemistry; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Imidazopyridine; Macaca mulatta; Male; Microsomes, Liver - metabolism; Pyridines - chemical synthesis; Pyridines - chemistry; Pyridines - pharmacokinetics; Pyridines - pharmacology; Rats, Wistar; Steroid 11-beta-Hydroxylase - antagonists & inhibitors; Structure-Activity Relationship; Hypertension; Heart failure; Imidazopyridine; Aldosterone; CYP11B2
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2016.12.003

[Display omitted]
The inhibition of aldosterone synthase (CYP11B2) may be an effective treatment of hypertension and heart failure, among other ailments. Previously reported benzimidazole CYP11B2 inhibitors led the way for bioisosteric imidazopyridines that are both potent and selective over CYP11B1.